Robert Coleman is an Oncology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 25 Feb 2010.
Clinical trials
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: National Cancer Institute (NCI)
- Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202523 payments$41,752openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year202528 payments$25,443openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 1998–2018 per NIH RePORTER. The latest:
- Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
University of Tx Md Anderson Can Ctr
FY2018$370,464P50CA217685 - Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
University of Tx Md Anderson Can Ctr
FY2017$351,941P50CA217685 - INTRAPERITONEAL AD5-P53 GENE THERAPY FOR OVARIAN CANCER
University of Texas Sw Med Ctr/dallas
FY1999R03CA079418
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”